Concepedia
Statistics
Publications
7
Citations
410
H-Index
Active since
2017
Affiliations
Harvard University(Current)
Center for Cancer Research
Massachusetts General Hospital
Broad Institute
University of California, San Francisco
Eranga R. Balasooriya is an author at Harvard University specializing in molecular biology, oncology, and tyrosine kinase inhibitors.
Publications per year
2017–2025
Honey Mediated Green Synthesis of Nanoparticles: New Era of Safe Nanotechnology
Eranga R. Balasooriya, Chanika D. Jayasinghe, Uthpala A. Jayawardena et al. · Journal of Nanomaterials · 2017 · 180 citations · Full text
Natural Sciences, Materials Science, Nanobiotechnology +6
Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
Qibiao Wu, Haley Ellis, Giulia Siravegna et al. · Clinical Cancer Research · 2023 · 78 citations · Full text
Medicine, Oncology, Pharmacology +17
BioID reveals an ATG9A interaction with ATG13-ATG101 in the degradation of p62/SQSTM1-ubiquitin clusters
Ashari Rashmi Kannangara, Daniel M. Poole, Colten M. McEwan et al. · EMBO Reports · 2021 · 65 citations · Full text
Life Sciences, Cell Biology, Molecular Biology +5
TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth
Tsz‐Yin Chan, Christina M. Egbert, Julia E. Maxson et al. · Nature Communications · 2021 · 32 citations · Full text
Life Sciences, Molecular Biology, Oncology +14
FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma
Yuanli Zhen, Kai Liu, Lei Shi et al. · Nature Communications · 2024 · 28 citations · Full text
Medicine, Cancer Biology, Oncology +17
1–5 of 7